Remove Drug Development Remove Organic Chemistry Remove Small Molecule
article thumbnail

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. 3D rendering of Antibody Drug Conjugate Molecules.

article thumbnail

Unlocking the potential of antibody drug conjugates

Drug Target Review

Raffaele Colombo, PhD, is Associate Director, Medicinal Chemistry at Zymeworks Inc. He has more than 14 years of experience in studying the design and synthesis of new payloads and drug-linkers for antibodies, small molecules, and nanoparticles. Dr Rich received a PhD in organic chemistry from the University of Alberta.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MicroED: From Powder to Structure in a Half-Hour

NIH Director's Blog: Drug Development

Now comes word of another absolutely incredible use of cryo-EM: determining with great ease and exquisite precision the structure of the smaller organic chemical compounds, or “small molecules,” that play such key roles in biological exploration and drug development.

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

There, I supported AI-enabled DD efforts in their small molecule portfolio. After graduating, Miles went on to work as a scientist on AstraZeneca’s Research and Development graduate programme, working on projects in biocatalysis, computational organic chemistry and machine learning for drug discovery.